Back to Search
Start Over
A snapshot on patient-reported outcome measures of people with multiple sclerosis on first-line therapies in a real world setting.
- Source :
- Neurological Sciences; Nov2020, Vol. 41 Issue 11, p3235-3241, 7p, 5 Charts
- Publication Year :
- 2020
-
Abstract
- Background: Patient-reported outcomes (PROs) may help patients and clinicians in selecting disease-modifying therapies (DMTs) for multiple sclerosis (MS). Objective: To evaluate PRO differences among first-line DMTs for relapsing-remitting (RR) people with MS (pwMS). Methods: Multicenter study. RR pwMS on first-line DMTs completed Fatigue Severity Scale (FSS), PROs Indices for MS (PRIMUS), 36-item Short-Form Health Survey (SF-36), treatment satisfaction questionnaire for medication (TSQM), Beck Depression Inventory-II (BDI-II), and Symbol Digit Modalities Test (SDMT). Differences among PROs across DMTs were tested by ANOVA. Multivariable linear regressions were used to investigate associations between PROs and the treatment group. Results: Two-hundred eighty pwMS were enrolled: 56% were on interferons (INF), 22% on dimethylfumarate (DMF), 13% on glatiramer acetate, and 9% on teriflunomide (Teri). Compared with INF, pwMS on Teri were the oldest, with higher disability, worst depression at BDI, worst cognitive performances at SDMT (p = 0.001), fatigue at FSS (p = 0.001), and activity limitation and quality of life respectively at PRIMUS (p = 0.005) and SF-36 Mental Composite Score (p < 0.001); pwMS on DMF reported highest side effects and, together with pwMS on Teri, better treatment satisfaction at TSQM. Conclusions: Compared with INF-treated patients, pwMS on DMF and Teri reported the best treatment satisfaction, although DMF-treated pwMS reported higher side effects and those on Teri the worst QoL and fatigue; however, the older age, higher disability and depression, and worse cognitive performance of pwMS on Teri suggest to be careful in evaluating these results. [ABSTRACT FROM AUTHOR]
- Subjects :
- MULTIPLE sclerosis
GLATIRAMER acetate
DRUG side effects
INTERFERONS
HEALTH surveys
Subjects
Details
- Language :
- English
- ISSN :
- 15901874
- Volume :
- 41
- Issue :
- 11
- Database :
- Complementary Index
- Journal :
- Neurological Sciences
- Publication Type :
- Academic Journal
- Accession number :
- 146478453
- Full Text :
- https://doi.org/10.1007/s10072-020-04367-9